Application
Fig1: Dot blot analysis of anti-CACNA1C on PVDF. 1ug, 2ug and 4ug of immunization peptides were given in this test. Anti-CACNA1C antibody was diluted with 1/500.Application
Fig2: ICC staining CACNA1C in SKOV-3 cells (green). The nuclear counter stain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilised with 0.25% Triton X100/PBS.Application
Fig3: Immunohistochemical analysis of paraffin-embedded rat brain tissue using anti-CACNA1C antibody. Counter stained with hematoxylin.Application
Fig4: Immunohistochemical analysis of paraffin-embedded human kidney tissue using anti-CACNA1C antibody. Counter stained with hematoxylin.Application
Fig5: Immunohistochemical analysis of paraffin-embedded human uterus tissue using anti-CACNA1C antibody. Counter stained with hematoxylin.Application
Fig6: Immunohistochemical analysis of paraffin-embedded mouse heart tissue using anti-CACNA1C antibody. Counter stained with hematoxylin.Application
Fig7: Flow cytometric analysis of SKOV-3 cells with CACNA1C antibody at 1/100 dilution (fuchsia) compared with an unlabelled control (cells without incubation with primary antibody; yellow). Alexa Fluor 488-conjugated goat anti-rabbit IgG was used as the secondary antibody.IHC
B, The protein expression of CACNA1C was negative in one case with rituximab resistance and positive in the other case with rituximab sensitivity, whereas CD20 protein expression was positive in both of them.WB
A and B, The interference with shRNA to CACNA1C reduced the percentage of rituximab-induced cell apoptosis (P < 0.05) in OCI-ly7 and OCI-Ly8 cell line.WB
B, CACNA1C protein was detected in anti-CD20 pull-down protein using Western blot after rituximab treatment of 2 hours in OCI-ly7 cells.WB
D, Proteasome inhibitor bortezomib (20 nmol/L) restored CD20 expression after administration of 6 hours in OCI-ly7 cells.WB
B, The ectopic expression of miR-363 reduced CACNA1C and CD20 protein expression in OCI-ly7 and OCI-ly8 cell lines.D, The knockout of miR-363 led to the upregulation of CACNA1C expression.| Product Name | CACNA1C |
|---|---|
| Antibody Type | Primary Antibodies |
| Product description | Pore-forming, alpha-1C subunit of the voltage-gated calcium channel that gives rise to L-type calcium currents. Mediates influx of calcium ions into the cytoplasm, and thereby triggers calcium release from the sarcoplasm. Plays an important role in excitation-contraction coupling in the heart. Required for normal heart development and normal regulation of heart rhythm. Required for normal contraction of smooth muscle cells in blood vessels and in the intestine. Essential for normal blood pressure regulation via its role in the contraction of arterial smooth muscle cells. Long-lasting (L-type) calcium channels belong to the 'high-voltage activated' (HVA) group (Probable). |
| Immunogen | Synthetic peptide within human CACNA1C aa 800-880. |
| Clonality | Polyclonal |
|---|---|
| Isotype | IgG |
| Host Species | Rabbit |
| Tested Applications | DotFCICCIHC |
| Dot Blot:1:500-1:1,000 ICC:1:500-1:2,000 IHC:1:50-1:200 FC:1:50-1:100 |
|
| Species Reactivity | HumanMouseRat |
| Concentration | 1mg/ml |
| Alternative Names | alpha-1 polypeptide antibody
cardiac muscle antibody
isoform 1 antibody
L type antibody
CAC1C_HUMAN antibody
CACH 2 antibody
CACH2 antibody
CACN 2 antibody
CACN2 antibody
CACNA1C antibody
CACNL1A1 antibody
Calcium channel antibody
Calcium channel cardic dihydropyridine sensitive alpha 1 subunit antibody
Calcium channel L type alpha 1 polypeptide isoform 1 cardiac muscle antibody
Calcium channel voltage dependent L type alpha 1C subunit antibody
CaV1.2 antibody
CCHL1A1 antibody
DHPR alpha 1 antibody
DHPR alpha 1 subunit antibody
LQT8 antibody
TS antibody
Voltage dependent L type calcium channel alpha 1C subunit antibody
Voltage dependent L type calcium channel subunit alpha 1C antibody
Voltage gated calcium channel alpha subunit Cav1.2 antibody
Voltage gated calcium channel subunit alpha Cav1.2 antibody
Voltage gated L type calcium channel Cav1.2 alpha 1 subunit splice variant 10* antibody Voltage-dependent L-type calcium channel subunit alpha-1C antibody Voltage-gated calcium channel subunit alpha Cav1.2 antibody |
|---|---|
| Molecular Weight(MW) | 249 kDa |
| Cellular Localization | Plasma membrane. |
Application
Fig1: Dot blot analysis of anti-CACNA1C on PVDF. 1ug, 2ug and 4ug of immunization peptides were given in this test. Anti-CACNA1C antibody was diluted with 1/500.
Application
Fig2: ICC staining CACNA1C in SKOV-3 cells (green). The nuclear counter stain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilised with 0.25% Triton X100/PBS.
Application
Fig3: Immunohistochemical analysis of paraffin-embedded rat brain tissue using anti-CACNA1C antibody. Counter stained with hematoxylin.
Application
Fig4: Immunohistochemical analysis of paraffin-embedded human kidney tissue using anti-CACNA1C antibody. Counter stained with hematoxylin.
Application
Fig5: Immunohistochemical analysis of paraffin-embedded human uterus tissue using anti-CACNA1C antibody. Counter stained with hematoxylin.
Application
Fig6: Immunohistochemical analysis of paraffin-embedded mouse heart tissue using anti-CACNA1C antibody. Counter stained with hematoxylin.
Application
Fig7: Flow cytometric analysis of SKOV-3 cells with CACNA1C antibody at 1/100 dilution (fuchsia) compared with an unlabelled control (cells without incubation with primary antibody; yellow). Alexa Fluor 488-conjugated goat anti-rabbit IgG was used as the secondary antibody.
IHC
B, The protein expression of CACNA1C was negative in one case with rituximab resistance and positive in the other case with rituximab sensitivity, whereas CD20 protein expression was positive in both of them.
WB
A and B, The interference with shRNA to CACNA1C reduced the percentage of rituximab-induced cell apoptosis (P < 0.05) in OCI-ly7 and OCI-Ly8 cell line.
WB
B, CACNA1C protein was detected in anti-CD20 pull-down protein using Western blot after rituximab treatment of 2 hours in OCI-ly7 cells.
WB
D, Proteasome inhibitor bortezomib (20 nmol/L) restored CD20 expression after administration of 6 hours in OCI-ly7 cells.
WB
B, The ectopic expression of miR-363 reduced CACNA1C and CD20 protein expression in OCI-ly7 and OCI-ly8 cell lines.D, The knockout of miR-363 led to the upregulation of CACNA1C expression.| Positive Control | SKOV-3, rat brain tissue, human kidney tissue, human uterus tissue, mouse heart tissue. |
|---|---|
| Application Notes | Dot Blot:1:500-1:1,000 ICC:1:500-1:2,000 IHC:1:50-1:200 FC:1:50-1:100 |
| Form | Liquid |
|---|---|
| Storage Instructions | Store at +4℃ after thawing. Aliquot store at -20℃. Avoid repeated freeze / thaw cycles. |
| Storage Buffer | 1*TBS (pH7.4), 0.5%BSA, 50%Glycerol. Preservative: 0.05% Sodium Azide. |
